Merck & Co doubles up on Ablynx research deal


Cut-down antibody drug developer Ablynx has agreed a second R&D partnership with US Pharma firm Merck & Co. Ablynx will receive €20 million (£17 million) up front, plus up to €10.7 million in research funding over three years. On top of that, milestone payments for any products that emerge from the collaboration could net the Belgian biotech up to €1.7 billion plus royalties.

This collaboration will focus on nanobodies (antibody fragments) directed against cancer, and builds on Merck’s previous collaboration with Ablynx for nanobodies that target voltage-gated ion channels. Ablynx also recently joined forces with Abbvie to develop nanobodies for treating rheumatoid arthritis and systemic lupus erythematosus.


Related Content

Merck & Co $460m ion channel deal

2 October 2012 Business

news image

Deal with Ablynx relates to antibody fragments

Business roundup

27 April 2011 Business

news image

Industry news, May 2011

Most Read

Coated nanoparticles show Alzheimer's promise

12 September 2014 News and Analysis

news image

Gold nanoparticles functionalised with amino acid polymer inhibit the growth of amyloid fibres associated with neurodegenerat...

First flexible graphene display paves the way for folding electronics

11 September 2014 News and Analysis

news image

Team behind the bendy e-reader display hope to have a full colour graphene-based smartphone style screen within a year

Most Commented

Does life play dice?

3 September 2014 The Crucible

news image

Philip Ball wonders whether life evolved to exploit quantum phenomena, or if it’s just in our nature

The trouble with boycotts

29 August 2014 Critical Point

news image

Cutting academic ties with a censured state can do more harm than good, says Mark Peplow